US · IMUX
Immunic, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10036
- Website
- immunic-therapeutics.com
Price · as of 2025-12-31
$9.65
Market cap 100.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $1,072.40 | ||||
| 2015 | $347.60 | ||||
| 2016 | $174.00 | ||||
| 2017 | $236.00 | $94.40 | |||
| 2018 | $9.28 | ||||
| 2019 | $8.33 | ||||
| 2020 | $16.26 | ||||
| 2021 | $10.45 | ||||
| 2022 | $1.66 | ||||
| 2023 | $1.53 | ||||
| 2024 | $1.15 | ||||
| 2025 | $1.06 |
AI valuation
Our deep-learning model estimates Immunic, Inc.'s (IMUX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $9.65
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMUX | Immunic, Inc. | $9.65 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| CBUS | Cibus, Inc. | $3.69 | 194.57M | +439% | -76% | — | — | -0.18 | 0.56 | 12.04 | -0.30 | — | -0.26 | 100.00% | -6062.79% | -5898.36% | -146.63% | -129.39% | -63.21% | 0.39 | -7.56 | 0.85 | 0.78 | -0.09 | -5827.00% | 13456.00% | 1647.00% | -114.67% | -2.92 | -29.47% | 0.00% | 0.00% | 0.00% | -0.28 | -1.24 | 17.17 | -5.24 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
About Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
- CEO
- Daniel Vitt
- Employees
- 91
- Beta
- 1.58
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $9.65) − 1 = — (DCF, example).